After spurning Sanofi for diabetes disappointment, Zealand nets FDA approval in severe hypoglycemia

About two and a half years after selling off royalties on a disappointing Sanofi-partnered diabetes drug, Zealand Pharma now has its own in-house program to boast about.

Zealand received FDA approval for dasiglucagon to treat severe hypoglycemia in children and adults with diabetes older than 6 years, the Danish biotech announced Monday. The drug will be called Zegalogue and a commercial launch is expected in late June.